Rs333

From SNPedia
Jump to: navigation, search

is asnp
is mentioned by
dbSNPrs333
nextbiors333
hapmaprs333
1000 genomesrs333
hgdprs333
ensemblrs333
gopubmedrs333
scholarrs333
googlers333
pharmgkbrs333
gwascentralrs333
openSNPrs333
23andMers333
23andMe allrs333
SNP Nexus

SNPshotrs333
SNPdbers333
MSV3drs333
GeneCCR5
Chromosome3
Orientationplus
Position46414947
ReferenceGRCh37 37.1/131
Max Magnitude4
Geno Mag Summary
(-;-) 4 very resistant to HIV
(-;GTCAGTATCAATTCTGGAAGAATTTCCAGACA) 2 resistant to HIV
(GTCAGTATCAATTCTGGAAGAATTTCCAGACA;GTCAGTATCAATTCTGGAAGAATTTCCAGACA) 0 common form

The chemokine receptor gene CCR5 plays an important role in many immune-related processes. Delta 32 rs333, designating the CCR5-delta32 deletion of 32 nucleotides from within the gene, is perhaps the most famous allele of CCR5. 23andMe tests for this by the name I3003626.

Individuals carrying one copy of the delta 32 allele are somewhat resistant to infection by HIV, the virus that causes AIDS, and individuals with 2 copies (delta 32 homozygotes, ~1% of Caucasians) are almost completely immune to infection by HIV. [PMID 8898752] The delta 32 allele may have been selected for in European populations because it confers resistance to plague (Black Death) or smallpox. [1]

NEJM suggests decreased risk of type 1 diabetes (odds ratio, 0.54; 95% CI, 0.40 to 0.72; P=1.88x10–6 with 2 df).

Does the CCR5-delta32 mutation have an entirely positive/protective role?

Probably not. In patients with abdominal aortic aneurysm (AAA), the major risk is a sudden rupture - which is quite often fatal. Individuals with the delta 32 variant are more likely to have aneurysms than non-carriers, and among patients with aneurysms, delta 32 carriers are more likely to rupture than to be diagnosed in time for surgical repair. [PMID 15557916]

Tests for CCR-delta32 are offered by FamilyTreeDNA (FAQ), 23andme, and possibly other direct-to-consumer genetics testing companies.


PharmGKBPA162360003
NameCCR5: 554_585del32, ?32, delta32
AnnotationThis variant (CCR5delta32 mutation) is associated with slower HIV disease progression in untreated patients. Heterozygous carriers tend to have lower rates of virological failure than patients with the common allele, but this benefit may not extend to the long term. Most reports indicated a favorable response to antiretroviral therapy for allele carriers.
GeneCCR5
Featue
EvidencePubMed ID:10463706; PubMed ID:10839590; PubMed ID:12447757; PubMed ID:15236615; PubMed ID:16312181
Drugs
DiseasesHIV, HIV Infections
Curation LevelCurated
Personal tools
Namespaces
Variants
Actions
Navigation
Toolbox